2023
Increased serum 1,25-dihydroxyvitamin D levels in gynecologic cancer patients with Post-Acute-Covid-Sequela (PASC)/Long COVID
Bellone S, Siegel E, Santin A. Increased serum 1,25-dihydroxyvitamin D levels in gynecologic cancer patients with Post-Acute-Covid-Sequela (PASC)/Long COVID. Gynecologic Oncology Reports 2023, 50: 101301. PMID: 38029227, PMCID: PMC10654147, DOI: 10.1016/j.gore.2023.101301.Peer-Reviewed Original ResearchGynecologic cancer patientsLong COVIDCancer patientsVitamin DPotent anti-inflammatory activityDihydroxyvitamin D levelsPost-acute sequelaeLong COVID symptomsAnti-inflammatory activityMental health impairmentControl cancer patientsExtrarenal conversionPost-AcuteControl patientsAcute infectionBone healthLC patientsPersistent inflammationD levelsCOVID symptomsImmune cellsPlasmatic levelsNovel biomarkersPatientsAbnormal levels
2022
Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti-PD-1 Immunotherapy in Endometrial Carcinoma.
Chow RD, Michaels T, Bellone S, Hartwich T, Bonazzoli E, Iwasaki A, Song E, Santin AD. Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti-PD-1 Immunotherapy in Endometrial Carcinoma. Cancer Discovery 2022, 13: 312-331. PMID: 36301137, PMCID: PMC9905265, DOI: 10.1158/2159-8290.cd-22-0686.Peer-Reviewed Original ResearchConceptsAnti-PD-1 immunotherapyImmune checkpoint blockadeMMRd tumorsNK cellsEndometrial carcinomaICB responseMutation burdenT-cell-driven immunityPhase II clinical trialMMRd endometrial cancersPD-1 inhibitorsMismatch repair-deficient cancersTumor-extrinsic factorsHigh response rateEffector CD8Antitumor immunityEndometrial cancerCancer immunotherapyImmune cellsLonger survivalClinical trialsPrimary resistanceT cellsResponse rateMMRdIn Silico Analysis of the Multi-Targeted Mode of Action of Ivermectin and Related Compounds
Aminpour M, Cannariato M, Preto J, Safaeeardebili M, Moracchiato A, Doria D, Donato F, Zizzi E, Deriu M, Scheim D, Santin A, Tuszynski J. In Silico Analysis of the Multi-Targeted Mode of Action of Ivermectin and Related Compounds. Computation 2022, 10: 51. DOI: 10.3390/computation10040051.Peer-Reviewed Original ResearchAnti-inflammatory pathwaySARS-CoV-2 virusAlpha 7 nicotinic acetylcholine receptorCholinergic anti-inflammatory pathwayAnti-viral effectsActivity of ivermectinNicotinic acetylcholine receptorsBiological mechanismsVagus nerveCytokine productionImmune cellsClinical studiesCD147 receptorViral penetrationAcetylcholine receptorsNeuronal tissueIvermectinMolecular targetsHigh affinitySpike glycoproteinPhysiological concentrationsMorbidityCOVID-19VirusReceptors